Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Pogue

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2020
Neratinib-Plus-Cetuximab in Quadruple-WT (<i>KRAS, NRAS, BRAF, PIK3CA</i>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib StudySamuel A Jacobs, James J Lee, Thomas J George, et al.
Journal of the National Cancer Institute|March 20, 2019
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast CancerRim S Kim, Nan Song, Patrick G Gavin, et al.
Breast Cancer Research : BCR|December 5, 2019
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2<sup>+</sup> breast cancerSamuel A Jacobs, André Robidoux, Jame Abraham, et al.
Breast Cancer Research : BCR|January 24, 2020
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancerSamuel A Jacobs, André Robidoux, Jame Abraham, et al.
Journal of the National Cancer Institute|November 23, 2013
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31Katherine L Pogue-Geile, Chungyeul Kim, Jong-Hyeon Jeong, et al.
Nature Cancer|June 27, 2025
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2<sup>+</sup> breast cancer that limits trastuzumab deruxtecan efficacyDong Hu, Xiaoshuang Lyu, Zheqi Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2018
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET TrialStephen Johnston, Shannon Puhalla, Duncan Wheatley, et al.
NPJ Breast Cancer|May 16, 2020
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working GroupMohamed Amgad, Elisabeth Specht Stovgaard, Eva Balslev, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 18, 2020
Neratinib-Plus-Cetuximab in Quadruple-WT (<i>KRAS, NRAS, BRAF, PIK3CA</i>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib StudySamuel A Jacobs, James J Lee, Thomas J George, et al.
Journal of the National Cancer Institute|March 20, 2019
Stromal Tumor-infiltrating Lymphocytes in NRG Oncology/NSABP B-31 Adjuvant Trial for Early-Stage HER2-Positive Breast CancerRim S Kim, Nan Song, Patrick G Gavin, et al.
Breast Cancer Research : BCR|December 5, 2019
NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2<sup>+</sup> breast cancerSamuel A Jacobs, André Robidoux, Jame Abraham, et al.
Breast Cancer Research : BCR|January 24, 2020
Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ breast cancerSamuel A Jacobs, André Robidoux, Jame Abraham, et al.
Journal of the National Cancer Institute|November 23, 2013
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31Katherine L Pogue-Geile, Chungyeul Kim, Jong-Hyeon Jeong, et al.
Nature Cancer|June 27, 2025
p95HER2, a truncated form of the HER2 oncoprotein, drives an immunosuppressive program in HER2<sup>+</sup> breast cancer that limits trastuzumab deruxtecan efficacyDong Hu, Xiaoshuang Lyu, Zheqi Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 8, 2018
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET TrialStephen Johnston, Shannon Puhalla, Duncan Wheatley, et al.
NPJ Breast Cancer|May 16, 2020
Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working GroupMohamed Amgad, Elisabeth Specht Stovgaard, Eva Balslev, et al.
Pageof 7